Up to 30% of U.S. patients carry genetic variations that reduce the effectiveness of clopidogrel, an antiplatelet medication sold under the brand name Plavix.
This new catheter-based device for lymphatic drainage showed early potential to be an effective treatment option for acute decompensated heart failure.
The REVEAL study has been assessing the sensitivity and specificity of iodine 124 evuzamitide (I 124 evuzamitide), a PET agent capable of visualizing signs of cardiac amyloidosis on imaging.
CT findings that have historically been deemed as concerning relative to PE might not hold as much weight when it comes to associated risks as previously thought, new analysis suggests.
The new technique mixes MRI signals at different gradient pulse strengths and timings, offering better visualization of differences in the way water molecules move through tissues.
Artificial intelligence tools have proven to be beneficial in detecting pulmonary nodules on chest CTs of adults, but less is known about their utility in pediatric populations.
Cardiologists and other physicians have always believed cardiac transthyretin amyloidosis, a progressive heart condition associated with a high mortality rate, was irreversible. Now, though, new evidence suggests that there may be hope.
Motives for the hesitancy are several—transportation concerns, informational inadequacies, historical wrongs—but effective resolutions can be quite simple.
Cedars-Sinai researchers are developing a deep-learning algorithm to personalize patient cardiac risk predictions in a patient-friendly, graphical report.
![A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]](/sites/default/files/styles/top_stories/public/2024-09/istock-1209664264.jpg.webp?itok=gQInU1vO)
